This is reported on the website of the RECOVERY test, one of the largest surveys conducted in the Great Britain to evaluate a range of potential treatments for the disease caused by the coronavirus.
Patients who have been affected by coronavirus are at higher risk of thrombosis due to an overreaction of the platelets, of cellular fragments, which help to stop bleeding. Aspirin is a anticoagulant agent and may reduce the risk of thrombosis, the RECOVERY trial website reported today.
«There is a clear rationale that leads us to believe that it (aspirin) can be beneficial and is safe, cheap and widely available,» said Peter Horby, co-principal investigator of the researchers involved in the trial, as reported by Reuters and quoted by the Athens News Agency.
At least 2,000 patients are expected to receive 150 mg of aspirin daily along with their usual treatment. Data from these patients will be compared with those from at least 2,000 other patients receiving only standard treatment, according to the website.
Other treatments being evaluated in the RECOVERY trial include the common antibiotic azithromycin and the Regeneron antibody cocktail used to treat outgoing US President Donald Trump when he was ill with coronavirus.
